ABSTRACT -Topiramate infrequently induces anion gap metabolic acidosis through carbonic anhydrase inhibition on the distal tubule of the nephron -a type 2 renal tubular acidosis. We report on a 40 years old woman previously healthy that developed significant asymptomatic metabolic acidosis during topiramate therapy at a dosage of 100mg/day for three months. Stopping medication was followed by normalization of the acid-base status within five weeks. This infrequent side effect appears unpredictable and should be given careful attention.
Topiramate was approved by the FDA (US -F o o d and Drug Administration) in 1996 for clinical use as an anticonvulsant drug. Since then, other clinical i ndications have been studied, such as the tre a tment of bipolar disord e r, or neuropathic pain syndro m e s re l i e f 1 , 2 , and migraine and cluster headache 3 -5 . As a consequence, it is likely that clinical use will tend t o expand progressively. Initially, significant adverse reactions to topiramate were related to the central nervous system (somnolence, nervousness, psychomotor slowing, memory problems, fatigue), or w e re gastrointestinal (nausea), ocular (diplopia, nystagmus) and neuromuscular (tre m o r, pare s t h e s i a ) . N e v e rtheless, since 1996, when it was approved by FDA, at least twelve reports were made relating metabolic acidosis to the use of topiramate, both in adults and in childre n 6 -1 7 . Finally, in December 20 03, FDA released a note about the risk of metabolic acidosis caused by topiramate usage 1 8 . Severe m etabolic acidosis can occur in patients under topiramate treatment, even when the daily dosage is low. The absence of relevant clinical symptoms re n d e r s it more difficult to recognize.
We present a case of severe asymptomatic metabolic acidosis due to topiramate in an adult woman.
CASE
A 46-year old previously healthy white woman came to our hospital with a complaint of intense chest pain for at least 5 days with tenderness on the site of the pain i n d icating traumatic origin. There were no other symptoms, and physical examination plus X-ray and laboratory evaluation excluded pleural or pulmonary disease. Later, a radiograph of the ribs, a chest CT scan and a radionuc l e a r bone scan showed a small traumatic lesion in the area of the pain. At the hospital entrance, her arterial blood gas analysis revealed metabolic acidosis: pH (7.31), pCO 2 (18.1 mmHg), pO 2 (121.0 mmHg), HCO 3 (8.9 mmol/L), CO 2 (9.5 mmol/L), base excess (-14.1 mmol/L). Renal function was normal (creatinine 0.9 mg/dL), urinary ultrasonography showed two apparently normal kidneys, non-fasting blood glucose was 112 mg/dL, potassium 3.9 mmol/L, sodium 140 mmol/L, chloride 107 mmo/L, serum amylase 54 U/L, AST 12 U/L, serum gamma-glutamyl transferase 12 U/L, prothrombin time 13.2 seconds, alkaline phosphatase 52 U/L, hemoglobin 12.8 g/dL, hematocrit 37.5%, leukocyte count 8400, normal urinalysis with urinary pH 5.0. Serum anion-gap was 13. We repeated the arterial blood gas analysis after 3 hours: pH (7.31), pCO 2 (24.1 mmHg), pO 2 (134.4 mmHg), HCO 3 (11.8 mmol/L), CO 2 ( 1 2 . 5 mmol/L), base excess (-11.9 mmol/L). Subsequent analysis revealed a normal serum lactate of 1.53 mmol/L, normal serum protein eletro p h o resis (with light hypoalbuminemia -3.05 g/dL), absent cryoglobulins, normal calciuria and phosphaturia.
She had been in use of topiramate as anti-vert i g i n o u s therapy for the last 3 months at a daily regular dosage of 100 mg. As vertigo symptoms ceased with this medication, she was reluctant to accept our indication to stop using it. However, on the 5 th day of hospitalization we obtained her consent to withdraw the medication. Art erial blood gas analyses or venous serum CO 2 
DISCUSSION
Metabolic acidosis in adults may be caused by increased acid generation (as in ketoacidosis and in lactic acidosis), by loss of bicarbonate (diarrhea o r type 2 renal tubular acidosis -RTA) or by diminished renal acid excretion (as in renal failure or in type 1 RTA). Type 1 and type 2 RTA are uncommon disorders, particularly in adults 19 , but in the absence of clear clinical evidence as in ketoacidosis, lactic acidosis or diarrhea, the presence of RTA should a l w a y s be considered in any patient with otherwise unexplained normal anion gap metabolic acidosis 20 .
RTA refers to the development of metabolic acidosis because of a defect in the ability of the re n a l tubules to perf o rm their normal response to acidemia: reabsorption of all the filtered bicarbonate and increased hydrogen excretion, the latter leading to regeneration of bicarbonate in the plasma. The type 1 RTA (distal) is characterized by impaire d acid secre t o ry capacity in the collecting tubules. This defect leads to an inability to excrete the daily acid load, resulting in progressive hydrogen ion retention and a drop in plasma bicarbonate concentration. In adults, this type 1 RTA is caused by some autoimmune disease (e.g., Sjögren's syndrome) or by some other condition associated with chronic h yp e rglobulinemia, none related to our patient. Ty p e 2 RTA (proximal) originates from the inability to reabsorb filtered bicarbonate in the proximal tubule norm a l l y. Since this reabsorption occurs in the p roximal tubule (85 to 90% of the filtered load), t h i s disturbance leads to an increased delivery of bicarbonate to the distal portion of the nephron. As the distal tubule is initially overwhelmed, there is bicarbonate spill into the final urine, leading to metabolic acidosis.
Type 2 RTA may occasionally present as an isolated defect or as part of Fanconi syndrome, a generalized proximal tubular dysfunction with bicarbonaturia, glucosuria, phosphaturia, uricosuria, a m inoaciduria, and tubular proteinuria. In adults, the most common causes of Fanconi syndrome are the e x c retion of light chains due to multiple myeloma (which may be latent); and the use of a carbonic anhydrase (CA) inhibitor (as acetazolamide). In our patient, proteinuria, glucosuria and phosphaturia w e re absent, stepping aside the possibility of Fanconi syndrome.
On the other hand, topiramate has been demonstrated to be an effective inhibitor of some CA isoe n z y m e s 1 4 , 2 1 , this being the mechanism assigned to the development of metabolic acidosis during its u s e 8 , 9 , 1 2 , 1 4 , 1 5 . A slight reduction in serum CO 2 by topiramate has been demonstrated as relatively common and generally asymptomatic 12, 17 , but marked d e c reases appear unusual, and are expected to occur when topiramate is associated to other acidogenic conditions, such as renal disease, diarrhea, ketogenic diet or surgery 12 . It was surprising that no other condition besides topiramate ingestion could be attributed to our patient. Anyway, the question remains why some people on topiramate may develop such a significant deficit of serum bicarbonate 9, 10, 15, 17 and others 12,17 not. As topiramate has a different power of inhibition over each CA isoenz y m e 2 1 , it seems reasonable to assume that diff e re nces between CA isoenzymes activity expression in different people could exist. Maybe this could explain the apparent diversity of susceptibility to metabolic acidosis in different persons.
Another diff e rence is the time re q u i red for seru m C O 2 to re t u rn to normal. Fakhoury et al. 8 re p o rt e d two patients who attempted suicide by taking a topiramate overdose. Their metabolic acidosis re t u rn e d to normal after 5-6 days. Stowe et al. 1 3 o b s e rved the n o rmalization of mental status (previously altere d , in a patient with metabolic acidosis due to topirama-te) 48 hours after drug withdrawal. When our patient was discharged from hospital seven days after topimarate withdrawal, she had an arterial serum CO 2 of 11.0 mmol/L. Normalization was detected 30 days l a t e r, but there was no opportunity for further labo r a t o ry evaluation during this period.
On the other hand, metabolic acidosis usually p rovokes some clinical manifestation such as hyperventilation and, when severe, mental confusion. I n our patient, despite an initial pH of 7.31 and seru m bicarbonate of 8.9 mmol/L, there were no clinical manifestations.
Since metabolic acidosis, when low-grade, may induce multiple endocrine and metabolic dysfunctions, and when severe may be a life-threatening condition, and also considering that its onset during topiramate therapy appears unpredictable, it would be a good practice to measure serum CO 2 or serum bicarbonate in a venous blood sample previously and at regular intervals when this drug m u s t be administered to any patient.
